Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)

Fig. 2

Values at baseline and follow-up by group for each variable and Treatment effects. Unadjusted values at baseline and 12 weeks follow-up, and the unadjusted treatment effect in the empagliflozin and placebo group with the adjusted p value. The box represents median with IQR, and whiskers represent 1.5 times the IQR. GDF-15 growth differentiation factor 15, HsCRP high-sensitivity C-reactive protein, HsTNT high-sensitivity Troponin T

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840